Based on ratings from 19 stock analysts, the Amgen Inc stock price is expected to increase by 9.31% in 12 months. This is calculated by using the average 12-month stock price forecast for Amgen Inc. The lowest target is $215.00 and the highest is $380.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 19 Wall Street analysts have assignedAMGN 11 buy ratings, 6 hold ratings, and 2 sell ratings. This means that analysts expect Amgen Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMGN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
mohit bansal Wells Fargo | Buy | $320.0 | maintained | Feb 16, 2024 |
elmar kraus DZ BANK AG | Buy | $333.0 | maintained | Feb 12, 2024 |
carter gould Barclays | Sell | $230.0 | maintained | Feb 7, 2024 |
yaron werber TD Cowen | Buy | $370.0 | maintained | Feb 7, 2024 |
salim syed Mizuho Securities | Hold | $223.0 | rated | Feb 7, 2024 |
david risinger Leerink Partners | Hold | $324.0 | downgraded | Feb 7, 2024 |
jay olson Oppenheimer | Buy | $380.0 | rated | Feb 7, 2024 |
brian skorney Robert W. Baird | Sell | $215.0 | maintained | Feb 7, 2024 |
christopher raymond Piper Sandler | Buy | $324.0 | rated | Feb 7, 2024 |
salveen richter Goldman Sachs | Buy | $350.0 | rated | Feb 7, 2024 |
terence flynn Morgan Stanley | Hold | $278.0 | maintained | Feb 7, 2024 |
evan seigerman BMO Capital | Buy | $343.0 | rated | Feb 6, 2024 |
gregory renza RBC Capital | Buy | $329.0 | maintained | Feb 6, 2024 |
michael yee Jefferies | Buy | $375.0 | rated | Feb 5, 2024 |
james shin Deutsche Bank | Hold | $285.0 | maintained | Feb 2, 2024 |
chris schott J.P. Morgan | Hold | $290.0 | maintained | Jan 29, 2024 |
colin bristow UBS | Hold | $314.0 | maintained | Jan 29, 2024 |
narumi nakagiri Daiwa | Buy | $320.0 | upgraded | Dec 21, 2023 |
robyn karnauskas Truist Financial | Buy | $320.0 | maintained | Nov 28, 2023 |
david toung Argus Research | Buy | $300.0 | maintained | Nov 6, 2023 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
When did it IPO
1983
Staff Count
26,700
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—General
CEO
Mr. Robert A. Bradway
Market Cap
$151.91B
In 2023, AMGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
AMAT-USD
$199.73
CMCSA-USD
$41.85
QCOM-USD
$152.69
ISRG-USD
$377.64
$198.94
LRCX-USD
$926.03